Literature DB >> 34549591

MRI Features Associated with Histology of Benign Prostatic Hyperplasia Nodules: Generation of a Predictive Model.

Jessica C Dai1, Tara N Morgan1, Ramy Goueli1, Daniel Parrott2, Alexander Kenigsberg1, Ryan J Mauck1, Claus G Roehrborn1, Douglas W Strand1, Daniel N Costa2, Jeffrey C Gahan1.   

Abstract

Background: Histologic phenotypic variation of benign prostatic hyperplasia (BPH) has been hypothesized to underlie response to medical therapy. We evaluate preoperative MRI of robot-assisted simple prostatectomy (RASP) specimens and determine imaging features associated with histologic phenotype. Materials and
Methods: All patients undergoing RASP from November 2015 to November 2019 with a multiparametric MRI ≤1 year before RASP were included. Patients without identifiable BPH nodules on histologic specimens were excluded. Histology slides were obtained from whole mount adenoma specimens and corresponding MRI were reviewed and graded independently by a blinded expert in BPH histopathology (D.W.S.) and an experienced radiologist specializing in prostate imaging (D.N.C.), respectively. Each nodule was assigned a phenotypic score on a 5-point Likert scale (1 = predominantly glandular; 5 = predominantly stromal) by each reviewer. Scores were compared using the sign test and univariate analysis. Signal intensity relative to background transition zone and nodule texture were noted on T2, diffusion-weighted imaging (DWI), and dynamic contrast-enhanced (DCE) imaging sequences. Univariate and multivariate stepwise linear regression analysis were conducted to identify MRI features associated with histology score. All analyses were performed using Statistical Analysis System (version 9.4).
Results: A total of 99 prostate nodules in 29 patients were included. Median phenotypic scores by histology and MRI were comparable (2, interquartile range [IQR] 2-3 vs 2, IQR 2-4, respectively; p = 0.63). Histology scores were positively correlated with MRI scores (Pearson's correlation 0.84, p < 0.0001). Multivariate stepwise linear regression analysis showed that low apparent diffusion coefficient (ADC) signal intensity (p < 0.001) and DCE wash-in (p = 0.03) were positively associated with more stromal histology, whereas ADC standard deviation (p = 0.03), DCE wash-out (p = 0.001), and heterogeneous T2 texture (p = 0.003) were associated with more glandular histology.
Conclusion: There is a strong correlation between MRI features and the histologic phenotype of BPH nodules. MRI may provide a noninvasive method to determine underlying BPH nodule histology.

Entities:  

Keywords:  MRI; benign prostatic hyperplasia; histology; lower urinary tract symptoms

Mesh:

Year:  2022        PMID: 34549591      PMCID: PMC8972022          DOI: 10.1089/end.2021.0397

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.619


  15 in total

1.  Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.

Authors:  K Isen; Z Sinik; T Alkibay; C Sezer; S Sözen; S Atilla; O Ataoglu ; S Isik
Journal:  Int J Urol       Date:  2001-02       Impact factor: 3.369

2.  On the prediction of the histologic composition of benign prostatic hyperplasia based on clinical and MRI parameters.

Authors:  R E Weijers; J V Zambon; A G Kessels; A P de Bruïne
Journal:  Prostate       Date:  1997-08-01       Impact factor: 4.104

3.  Precision and accuracy of magnetic resonance imaging for lobar classification of benign prostatic hyperplasia.

Authors:  Neil F Wasserman; Eric Niendorf; Benjamin Spilseth
Journal:  Abdom Radiol (NY)       Date:  2019-07

Review 4.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

5.  Use of MRI for Lobar Classification of Benign Prostatic Hyperplasia: Potential Phenotypic Biomarkers for Research on Treatment Strategies.

Authors:  Neil F Wasserman; Benjamin Spilseth; Jafar Golzarian; Gregory J Metzger
Journal:  AJR Am J Roentgenol       Date:  2015-09       Impact factor: 3.959

6.  An Update of the American Urological Association White Paper on the Prevention and Treatment of the More Common Complications Related to Prostate Biopsy.

Authors:  Michael A Liss; Behfar Ehdaie; Stacy Loeb; Maxwell V Meng; Jay D Raman; Vanessa Spears; Sean P Stroup
Journal:  J Urol       Date:  2017-03-29       Impact factor: 7.450

7.  Benign prostatic hyperplasia: value of MR imaging for determining histologic type.

Authors:  J Ishida; K Sugimura; H Okizuka; Y Kaji; M Moriyama; S Nagaoka; M Mizutani; T Ishida
Journal:  Radiology       Date:  1994-02       Impact factor: 11.105

8.  The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia.

Authors:  E Shapiro; M J Becich; V Hartanto; H Lepor
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

9.  Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.

Authors:  K M C Verhamme; J P Dieleman; G S Bleumink; J van der Lei; M C J M Sturkenboom; W Artibani; B Begaud; R Berges; A Borkowski; C R Chappel; A Costello; P Dobronski; R D T Farmer; F Jiménez Cruz; U Jonas; K MacRae; L Pientka; F F H Rutten; C P van Schayck; M J Speakman; M C Sturkenboom; P Tiellac; A Tubaro; G Vallencien; R Vela Navarrete
Journal:  Eur Urol       Date:  2002-10       Impact factor: 20.096

Review 10.  Role of mpMRI in Benign Prostatic Hyperplasia Assessment and Treatment.

Authors:  Stephanie M Walker; Baris Turkbey
Journal:  Curr Urol Rep       Date:  2020-10-26       Impact factor: 3.092

View more
  1 in total

1.  PSA density is associated with BPH cellular composition.

Authors:  Liwei Jia; Douglas W Strand; Ramy S Goueli; Jeffrey C Gahan; Claus G Roehrborn; Ryan J Mauck
Journal:  Prostate       Date:  2022-06-02       Impact factor: 4.012

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.